Bioasis has entered into a licensing agreement granting Prothena certain rights to use the Bioasis xB3 platform technology for neuroscience targets.

Under the terms of the agreement, Bioasis will receive an upfront payment of US$1 million and may receive up to an additional US$33 million in options exercise, regulatory and commercial milestone payments, plus additional royalties on net sales from the licensed products.